{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:49:06Z","timestamp":1765057746174,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T00:00:00Z","timestamp":1615075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T00:00:00Z","timestamp":1615075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","award":["P30CA134274"],"award-info":[{"award-number":["P30CA134274"]}]},{"name":"The State of Maryland\u2019s Cigarette Restitution Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00280-021-04252-y","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T02:02:32Z","timestamp":1615082552000},"page":"817-826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens"],"prefix":"10.1007","volume":"87","author":[{"given":"Sarah M.","family":"Kashanian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5706-1109","authenticated-orcid":false,"given":"Noa G.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-4345","authenticated-orcid":false,"given":"Ciera L.","family":"Patzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Cornu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9018-3722","authenticated-orcid":false,"given":"Alison","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-8489","authenticated-orcid":false,"given":"Madhurima","family":"Koka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9254-0095","authenticated-orcid":false,"given":"Sandrine","family":"Niyongere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-7727","authenticated-orcid":false,"given":"Vu H.","family":"Duong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9499-1348","authenticated-orcid":false,"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6733-6914","authenticated-orcid":false,"given":"Jummai","family":"Apata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4169-7978","authenticated-orcid":false,"given":"Farin","family":"Kamangar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3769-3210","authenticated-orcid":false,"given":"Ashkan","family":"Emadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,7]]},"reference":[{"key":"4252_CR1","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/ajh.25229","volume":"93","author":"SE Siegel","year":"2018","unstructured":"Siegel SE, Advani A, Seibel N et al (2018) Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens. Am J Hematol 93:1254\u20131266. https:\/\/doi.org\/10.1002\/ajh.25229","journal-title":"Am J Hematol"},{"key":"4252_CR2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/leu.2014.229","volume":"29","author":"DJ DeAngelo","year":"2015","unstructured":"DeAngelo DJ, Stevenson KE, Dahlberg SE et al (2015) Long-term outcome of a pediatric-inspired regimen used for adults aged 18\u201350 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 29:526\u2013534. https:\/\/doi.org\/10.1038\/leu.2014.229","journal-title":"Leukemia"},{"key":"4252_CR3","volume-title":"Cancer pharmacology: an illustrated manual of anticancer drugs","author":"C Lu","year":"2020","unstructured":"Lu C, Karp J, Emadi A (2020) Antimetabolites: hydroxyurea, pyrimidine and purine analogs, and l-asparaginase. In: Emadi A, Karp JE (eds) Cancer pharmacology: an illustrated manual of anticancer drugs. Demos Medical, New York"},{"key":"4252_CR4","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","volume":"99","author":"VI Avramis","year":"2002","unstructured":"Avramis VI, Sencer S, Periclou AP et al (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children\u2019s Cancer Group study. Blood 99:1986\u20131994. https:\/\/doi.org\/10.1182\/blood.V99.6.1986","journal-title":"Blood"},{"key":"4252_CR5","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","volume":"16","author":"AE Place","year":"2015","unstructured":"Place AE, Stevenson KE, Vrooman LM et al (2015) Intravenous pegylated asparaginase versus intramuscular native Escherichia colil-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05\u2013001): a randomised, open-label phase 3 trial. Lancet Oncol 16:1677\u20131690. https:\/\/doi.org\/10.1016\/S1470-2045(15)00363-0","journal-title":"Lancet Oncol"},{"key":"4252_CR6","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","volume":"109","author":"M Wetzler","year":"2007","unstructured":"Wetzler M, Sanford BL, Kurtzberg J et al (2007) Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and leukemia group B study 9511. Blood 109:4164\u20134167. https:\/\/doi.org\/10.1182\/blood-2006-09-045351","journal-title":"Blood"},{"key":"4252_CR7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/00043426-200306000-00011","volume":"25","author":"M Kieslich","year":"2003","unstructured":"Kieslich M, Porto L, Lanfermann H et al (2003) Cerebrovascular complications of l-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 25:484\u2013487. https:\/\/doi.org\/10.1097\/00043426-200306000-00011","journal-title":"J Pediatr Hematol Oncol"},{"key":"4252_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/ejh.12600","volume":"96","author":"I Aldoss","year":"2016","unstructured":"Aldoss I, Douer D, Behrendt CE et al (2016) Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol 96:375\u2013380. https:\/\/doi.org\/10.1111\/ejh.12600","journal-title":"Eur J Haematol"},{"key":"4252_CR9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3109\/10428194.2015.1101098","volume":"57","author":"N Hijiya","year":"2016","unstructured":"Hijiya N, Van Der Sluis IM (2016) Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma 57:748\u2013757. https:\/\/doi.org\/10.3109\/10428194.2015.1101098","journal-title":"Leuk Lymphoma"},{"key":"4252_CR10","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","volume":"52","author":"W Stock","year":"2011","unstructured":"Stock W, Douer D, Deangelo DJ et al (2011) Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma 52:2237\u20132253. https:\/\/doi.org\/10.3109\/10428194.2011.596963","journal-title":"Leuk Lymphoma"},{"key":"4252_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1160\/TH14-04-0372","volume":"113","author":"V De Stefano","year":"2015","unstructured":"De Stefano V, Za T, Ciminello A et al (2015) Haemostatic alterations induced by treatment with asparaginases and clinical consequences. Thromb Haemost 113:247\u2013261. https:\/\/doi.org\/10.1160\/TH14-04-0372","journal-title":"Thromb Haemost"},{"key":"4252_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/1078155219838316","volume":"26","author":"NA Bade","year":"2020","unstructured":"Bade NA, Lu C, Patzke CL et al (2020) Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management. J Oncol Pharm Pract 26:74\u201392. https:\/\/doi.org\/10.1177\/1078155219838316","journal-title":"J Oncol Pharm Pract"},{"key":"4252_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","volume":"152","author":"RF Grace","year":"2011","unstructured":"Grace RF, Dahlberg SE, Neuberg D et al (2011) The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 152:452\u2013459. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08524.x","journal-title":"Br J Haematol"},{"key":"4252_CR14","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/10428194.2018.1519811","volume":"60","author":"J Chen","year":"2019","unstructured":"Chen J, Ngo D, Aldoss I et al (2019) Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia. Leuk Lymphoma 60:1187\u20131192. https:\/\/doi.org\/10.1080\/10428194.2018.1519811","journal-title":"Leuk Lymphoma"},{"key":"4252_CR15","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1080\/10428190410001693588","volume":"45","author":"MA Elliott","year":"2004","unstructured":"Elliott MA, Wolf RC, Hook CC et al (2004) Thromboembolism in adults with acute lymphoblastic leukemia during induction with l-asparaginase-containing multi-agent regimens: Incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma 45:1545\u20131551. https:\/\/doi.org\/10.1080\/10428190410001693588","journal-title":"Leuk Lymphoma"},{"key":"4252_CR16","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.3109\/10428194.2016.1165815","volume":"57","author":"K Farrell","year":"2016","unstructured":"Farrell K, Fyfe A, Allan J et al (2016) An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events. Leuk Lymphoma 57:2568\u20132574. https:\/\/doi.org\/10.3109\/10428194.2016.1165815","journal-title":"Leuk Lymphoma"},{"key":"4252_CR17","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3324\/haematol.12948","volume":"93","author":"M Hunault-Berger","year":"2008","unstructured":"Hunault-Berger M, Chevallier P, Delain M et al (2008) Changes in antithrombin and fibrinogen levels during induction chemotherapy with l-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: The CAPELAL study. Haematologica 93:1488\u20131494. https:\/\/doi.org\/10.3324\/haematol.12948","journal-title":"Haematologica"},{"key":"4252_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood.2020004919","volume":"136","author":"C Orvain","year":"2020","unstructured":"Orvain C, Balsat M, Tavernier E et al (2020) Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 Study. Blood 136:328\u2013338. https:\/\/doi.org\/10.1182\/blood.2020004919","journal-title":"Blood"},{"key":"4252_CR19","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1182\/blood-2008-08-175745","volume":"113","author":"GH Ku","year":"2009","unstructured":"Ku GH, White RH, Chew HK et al (2009) Venous thromboembolism in patients with acute leukemia: Incidence, risk factors, and effect on survival. Blood 113:3911\u20133917. https:\/\/doi.org\/10.1182\/blood-2008-08-175745","journal-title":"Blood"},{"key":"4252_CR20","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/leu.2012.290","volume":"27","author":"E Truelove","year":"2013","unstructured":"Truelove E, Fielding AK, Hunt BJ (2013) The coagulopathy and thrombotic risk associated with l-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia 27:553\u2013559. https:\/\/doi.org\/10.1038\/leu.2012.290","journal-title":"Leukemia"},{"key":"4252_CR21","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/ajh.24130","volume":"90","author":"MA Couturier","year":"2015","unstructured":"Couturier MA, Huguet F, Chevallier P et al (2015) Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: the GRAALL experience. Am J Hematol 90:986\u2013991. https:\/\/doi.org\/10.1002\/ajh.24130","journal-title":"Am J Hematol"},{"key":"4252_CR22","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/cam4.1094","volume":"6","author":"S Roininen","year":"2017","unstructured":"Roininen S, Laine O, Kauppila M et al (2017) A minor role of asparaginase in predisposing to cerebral venous thromboses in adult acute lymphoblastic leukemia patients. Cancer Med 6:1275\u20131285. https:\/\/doi.org\/10.1002\/cam4.1094","journal-title":"Cancer Med"},{"key":"4252_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1055\/s-0032-1315758","volume":"38","author":"F Dentali","year":"2012","unstructured":"Dentali F, Sironi A, Ageno W et al (2012) Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. Semin Thromb Hemost 38:535\u2013547. https:\/\/doi.org\/10.1055\/s-0032-1315758","journal-title":"Semin Thromb Hemost"},{"key":"4252_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-014-0237-8","volume":"13","author":"A Etemadi","year":"2015","unstructured":"Etemadi A, Kamangar F, Islami F et al (2015) Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study. BMC Med 13:1\u20137. https:\/\/doi.org\/10.1186\/s12916-014-0237-8","journal-title":"BMC Med"},{"key":"4252_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1046\/j.1537-2995.2001.41010056.x","volume":"41","author":"A Moeller","year":"2001","unstructured":"Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V (2001) Influence of ABO blood groups on primary hemostasis. Transfusion 41:56\u201360. https:\/\/doi.org\/10.1046\/j.1537-2995.2001.41010056.x","journal-title":"Transfusion"},{"key":"4252_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1365-3148.2001.00315.x","volume":"11","author":"J O\u2019Donnell","year":"2001","unstructured":"O\u2019Donnell J, Laffan MA (2001) The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med 11:343\u2013351. https:\/\/doi.org\/10.1046\/j.1365-3148.2001.00315.x","journal-title":"Transfus Med"},{"key":"4252_CR27","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1097\/MPH.0000000000000333","volume":"37","author":"T Mizrahi","year":"2015","unstructured":"Mizrahi T, Leclerc JM, David M et al (2015) ABO group as a thrombotic risk factor in children with acute lymphoblastic leukemia: a retrospective study of 523 patients. J Pediatr Hematol Oncol 37:e328\u2013e332. https:\/\/doi.org\/10.1097\/MPH.0000000000000333","journal-title":"J Pediatr Hematol Oncol"},{"key":"4252_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.thromres.2016.05.015","volume":"144","author":"M Spavor","year":"2016","unstructured":"Spavor M, Halton J, Dietrich K et al (2016) Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: a risk model. Thromb Res 144:27\u201331. https:\/\/doi.org\/10.1016\/j.thromres.2016.05.015","journal-title":"Thromb Res"},{"key":"4252_CR29","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"4252_CR30","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissue","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissue. IARC Press, Lyon, France"},{"key":"4252_CR31","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health NCI Common Terminology Criteria for Adverse Events (CTCAE). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 6 Jun 2020"},{"key":"4252_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.thromres.2018.02.150.Obesity","volume":"165","author":"S Prasca","year":"2020","unstructured":"Prasca S, Carmona R, Ji L et al (2020) Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia. Thromb Res 165:44\u201350. https:\/\/doi.org\/10.1016\/j.thromres.2018.02.150.Obesity","journal-title":"Thromb Res"},{"key":"4252_CR33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/bjh.14048","volume":"174","author":"X Duarte","year":"2016","unstructured":"Duarte X, Esteves S, Neto AM, Pereira F (2016) Incidence and risk factors for central nervous system thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study. Br J Haematol 174:280\u2013291. https:\/\/doi.org\/10.1111\/bjh.14048","journal-title":"Br J Haematol"},{"key":"4252_CR34","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.gde.2016.03.011","volume":"74","author":"M Vazqueza","year":"2015","unstructured":"Vazqueza M, Catalan-Dibenea J, Zlotnik A (2015) B cells responses and cytokine production are regulated by their immune microenvironment. Cytokine 74:318\u2013326. https:\/\/doi.org\/10.1016\/j.gde.2016.03.011","journal-title":"Cytokine"},{"key":"4252_CR35","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1200\/JCO.2013.50.2708","volume":"32","author":"D Douer","year":"2014","unstructured":"Douer D, Aldoss I, Lunning MA et al (2014) Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol 32:905\u2013911. https:\/\/doi.org\/10.1200\/JCO.2013.50.2708","journal-title":"J Clin Oncol"},{"key":"4252_CR36","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","volume":"109","author":"D Douer","year":"2007","unstructured":"Douer D, Yampolsky H, Cohen LJ et al (2007) Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 109:2744\u20132750. https:\/\/doi.org\/10.1182\/blood-2006-07-035006","journal-title":"Blood"},{"key":"4252_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26555","author":"R Lebovic","year":"2017","unstructured":"Lebovic R, Pearce N, Lacey L et al (2017) Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.26555","journal-title":"Pediatr Blood Cancer"},{"key":"4252_CR38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1078155217701291","volume":"24","author":"TN Christ","year":"2018","unstructured":"Christ TN, Stock W, Knoebel RW (2018) Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract 24:299\u2013308. https:\/\/doi.org\/10.1177\/1078155217701291","journal-title":"J Oncol Pharm Pract"},{"key":"4252_CR39","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1182\/blood-2018-01-827949","volume":"131","author":"CU Rank","year":"2018","unstructured":"Rank CU, Toft N, Tuckuviene R et al (2018) Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood 131:2475\u20132484. https:\/\/doi.org\/10.1182\/blood-2018-01-827949","journal-title":"Blood"},{"key":"4252_CR40","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1182\/blood.V112.11.302.302","volume":"112","author":"N Goekbuget","year":"2008","unstructured":"Goekbuget N, Baumann A, Beck J et al (2008) PEG-asparaginase in adult acute lymphoblastic leukemia (ALL): efficacy and feasibility analysis with increasing dose levels. Blood 112:302. https:\/\/doi.org\/10.1182\/blood.V112.11.302.302","journal-title":"Blood"},{"key":"4252_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1600-0609.1996.tb00290.x","volume":"56","author":"U Nowak-G\u00f6ttl","year":"2009","unstructured":"Nowak-G\u00f6ttl U, Kun N, Wolff JEA et al (2009) Inhibition of hypercoagulation by antithrombin substitution in E. colil-asparaginase-treated children. Eur J Haematol 56:35\u201338. https:\/\/doi.org\/10.1111\/j.1600-0609.1996.tb00290.x","journal-title":"Eur J Haematol"},{"key":"4252_CR42","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/pbc.21222","volume":"50","author":"B Meister","year":"2008","unstructured":"Meister B, Kropshofer G, Klein-Franke A et al (2008) Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 50:298\u2013303. https:\/\/doi.org\/10.1002\/pbc.21222","journal-title":"Pediatr Blood Cancer"},{"key":"4252_CR43","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1365-2141.2006.06209.x","volume":"134","author":"S Kuhle","year":"2006","unstructured":"Kuhle S, Lau A, Bajzar L et al (2006) Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with l-asparaginase: an in vitro study. Br J Haematol 134:526\u2013531. https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06209.x","journal-title":"Br J Haematol"},{"key":"4252_CR44","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.thromres.2019.11.002","volume":"184","author":"KB Jarvis","year":"2019","unstructured":"Jarvis KB, LeBlanc M, Tulstrup M et al (2019) Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia\u2014a NOPHO ALL2008 study. Thromb Res 184:92\u201398. https:\/\/doi.org\/10.1016\/j.thromres.2019.11.002","journal-title":"Thromb Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04252-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04252-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04252-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T06:03:34Z","timestamp":1620626614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04252-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,7]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["4252"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04252-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2021,3,7]]},"assertion":[{"value":"24 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AE: research grants from Jazz Pharmaceuticals, Servier and NewLink Genetics, global oncology advisory board member for Amgen and has served as an advisory board member for Genentech and Servier. AD: Amgen Speaker Bureau, a consultant for Heron Therapeutics and Teva Pharmaceuticals. All other authors declare that they have no relevant competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The Institutional Review Board at the study center approved this study. As this was a retrospective study, informed consent could not be obtained from all patients included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publication"}}]}}